BioSpace News Archive

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development.

Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported second quarter 2022 financial results and business highlights.

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022, after the close of the U.S. financial markets.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 26,100 shares of Karyopharm’s common stock and an aggregate of 18,000 restricted stock units to eight newly-hired employees.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 18,000 shares of the company’s common stock to one new employee.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s Compensation Committee granted, in connection with the previously announced appointments of Volker Knappertz, M.D. as Executive Vice President of Research and Development and Scott Habig as Chief Commercial Officer, an aggregate of 488,095 inducement stock options and an aggregate of 290,343 inducement restricted stock units.

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX) will report its financial results for the second quarter ended June 30, 2022 before market on Tuesday, August 16, 2022.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter of 2022.

The American Board of Obstetrics and Gynecology announces the planned retirement of George D. Wendel, Jr., MD, Executive Director, effective December 31, 2023.